当前位置:首页 - 行情中心 - 昭衍新药(603127) - 财务分析 - 利润表

昭衍新药

(603127)

  

流通市值:345.22亿  总市值:411.73亿
流通股本:2.27亿   总股本:2.71亿

利润表

按照会计年度查询:
报告期2021-03-312020-12-312020-09-302020-06-30
一、营业总收入200,992,535.411,075,904,934.98631,513,285.48397,354,998.31
营业收入200,992,535.411,075,904,934.98631,513,285.48397,354,998.31
二、营业总成本111,324,851.53804,305,793.58522,183,460.31327,067,880.97
营业成本97,328,314.02523,092,081.71317,147,386.78198,024,267.05
营业税金及附加1,605,433.146,535,064.834,736,912.263,549,453.59
销售费用3,197,669.4912,907,276.429,785,663.516,490,628.2
管理费用67,109,647.64208,634,972.93140,953,521.9192,156,627.59
财务费用-67,795,020.992,477,430.66674,486.41-1,207,791.95
资产减值损失-1,112,952.02-1,510,231.78-2,289,912.55-2,301,129.65
三、其他经营收益-30,711,088.8828,511,243.6434,201,771.742,137,296.35
允许价值变动净收益902,485.1758,945,751.322,444,803.99832,017.7
投资净收益1,787,131.491,523,736.291,511,544.511,511,544.51
联营、合营企业投资收益--------
汇兑净收益--------
四、营业利润107,803,457.78361,118,086.56133,614,833.0484,307,594.93
营业外收入6,70516,446.5114,309.647,790
营业外支出3,774,197.84562,429.36534,239.17374,398.78
非流动资产处置净损失--------
五、利润总额104,035,964.94360,572,103.71133,094,903.5183,940,986.15
所得税10,935,949.6246,944,339.7715,887,770.318,677,419.94
未确认的投资损失--------
六、净利润(百万元)93.36315.01118.2875.66
少数股东损益-257,249.94-1,386,132.37-1,076,941.14-401,228.1
归属于母公司股东的净利润93,357,265.26315,013,896.31118,284,074.3475,664,794.31
七、每股收益0.391.40.520.34
基本每股收益0.391.40.520.34
稀释每股收益0.381.390.520.33
TOP↑